Parkinson disease
Conditions
Brief summary
the difference in binding of the radiotracer [11C]SB207145 to the 5-HT4 receptor between Parkinsonian patients and control subjects. For each subject, the specific binding of the tracer will be calculated for each voxel with respect to a reference zone (the white matter of the cerebellum).
Detailed description
the description of the relationship between the level of expression of the tracer and the clinical scores on the scales of motor, non-motor, cognitive and psycho-behavioural symptoms., the description of the relationship between the expression level of the tracer and the polymorphism data.
Interventions
DRUG[C11]-SB207145
Sponsors
Hospices Civils De Lyon
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the difference in binding of the radiotracer [11C]SB207145 to the 5-HT4 receptor between Parkinsonian patients and control subjects. For each subject, the specific binding of the tracer will be calculated for each voxel with respect to a reference zone (the white matter of the cerebellum). | — |
Secondary
| Measure | Time frame |
|---|---|
| the description of the relationship between the level of expression of the tracer and the clinical scores on the scales of motor, non-motor, cognitive and psycho-behavioural symptoms., the description of the relationship between the expression level of the tracer and the polymorphism data. | — |
Countries
France
Outcome results
None listed